$CORT
CORCEPT THERAPEUTICS INC

2022 Q4 Form 10-Q Financial Statement

#000162828022028203 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $103.1M $101.7M
YoY Change 4.28% 5.82%
Cost Of Revenue $1.480M $1.339M
YoY Change 9.31% 5.02%
Gross Profit $101.6M $100.4M
YoY Change 4.21% 5.83%
Gross Profit Margin 98.56% 98.68%
Selling, General & Admin $42.32M $35.16M
YoY Change 31.09% 15.16%
% of Gross Profit 41.67% 35.03%
Research & Development $36.75M $33.29M
YoY Change 28.88% 18.51%
% of Gross Profit 36.18% 33.16%
Depreciation & Amortization $183.0K $195.0K
YoY Change -36.68% -27.51%
% of Gross Profit 0.18% 0.19%
Operating Expenses $79.08M $68.46M
YoY Change 30.05% 16.77%
Operating Profit $22.50M $31.93M
YoY Change -38.63% -11.86%
Interest Expense $1.777M $1.070M
YoY Change 2368.06% 1386.11%
% of Operating Profit 7.9% 3.35%
Other Income/Expense, Net $1.070M
YoY Change 1386.11%
Pretax Income $24.28M $33.00M
YoY Change -33.92% -9.09%
Income Tax $7.675M -$1.600M
% Of Pretax Income 31.62% -4.85%
Net Earnings $16.60M $34.61M
YoY Change -48.21% 13.58%
Net Earnings / Revenue 16.11% 34.02%
Basic Earnings Per Share $0.32
Diluted Earnings Per Share $0.14 $0.30
COMMON SHARES
Basic Shares Outstanding 107.6M shares 107.1M shares
Diluted Shares Outstanding 116.6M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $431.7M $396.3M
YoY Change 93.11% 9.67%
Cash & Equivalents $66.33M $50.24M
Short-Term Investments $365.3M $346.0M
Other Short-Term Assets $30.42M $20.68M
YoY Change 194.95% 128.08%
Inventory $6.100M $6.046M
Prepaid Expenses
Receivables $31.06M $29.41M
Other Receivables $0.00 $0.00
Total Short-Term Assets $499.3M $452.4M
YoY Change 87.36% 12.57%
LONG-TERM ASSETS
Property, Plant & Equipment $633.0K $801.0K
YoY Change -36.83% -34.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.947M $4.895M
YoY Change -95.59% -96.34%
Other Assets $5.058M $5.081M
YoY Change 64.06% 23.75%
Total Long-Term Assets $84.18M $80.85M
YoY Change -46.48% -55.94%
TOTAL ASSETS
Total Short-Term Assets $499.3M $452.4M
Total Long-Term Assets $84.18M $80.85M
Total Assets $583.4M $533.3M
YoY Change 37.68% -8.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.98M $8.178M
YoY Change 73.36% 24.7%
Accrued Expenses $30.80M $29.41M
YoY Change 11.33% 20.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.49M $53.07M
YoY Change 52.48% 18.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.097M $6.823M
YoY Change 2124.21% 1552.06%
Total Long-Term Liabilities $9.097M $6.823M
YoY Change 2124.21% 1552.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.49M $53.07M
Total Long-Term Liabilities $9.097M $6.823M
Total Liabilities $81.59M $59.89M
YoY Change 70.15% 32.59%
SHAREHOLDERS EQUITY
Retained Earnings $296.4M $279.8M
YoY Change 52.02% 71.74%
Common Stock $131.0K $649.0M
YoY Change -99.98% 13.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $501.8M $473.4M
YoY Change
Total Liabilities & Shareholders Equity $583.4M $533.3M
YoY Change 37.68% -8.91%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $16.60M $34.61M
YoY Change -48.21% 13.58%
Depreciation, Depletion And Amortization $183.0K $195.0K
YoY Change -36.68% -27.51%
Cash From Operating Activities $33.39M $33.65M
YoY Change -32.45% -30.91%
INVESTING ACTIVITIES
Capital Expenditures $31.00K -$351.0K
YoY Change -147.69% 120.75%
Acquisitions
YoY Change
Other Investing Activities -$17.21M -$4.439M
YoY Change -112.25% -82.69%
Cash From Investing Activities -$17.24M -$4.790M
YoY Change -112.27% -81.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -61.00K -13.96M
YoY Change -99.97% -40.95%
NET CHANGE
Cash From Operating Activities 33.39M 33.65M
Cash From Investing Activities -17.24M -4.790M
Cash From Financing Activities -61.00K -13.96M
Net Change In Cash 16.09M 14.90M
YoY Change -194.23% -2107.68%
FREE CASH FLOW
Cash From Operating Activities $33.39M $33.65M
Capital Expenditures $31.00K -$351.0K
Free Cash Flow $33.36M $34.00M
YoY Change -32.6% -30.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001088856
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50679
dei Entity Registrant Name
EntityRegistrantName
CORCEPT THERAPEUTICS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0487658
dei Entity Address Address Line1
EntityAddressAddressLine1
149 Commonwealth Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
327-3270
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
CORT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
107649854 shares
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50243000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77617000 usd
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
346019000 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
145918000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29414000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27625000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
6046000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
4988000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20680000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10315000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
452402000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
266463000 usd
CY2022Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
11027000 usd
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12962000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1707000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
514000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
801000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1002000 usd
CY2022Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
4895000 usd
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
112277000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5081000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3083000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
57342000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
27455000 usd
CY2022Q3 us-gaap Assets
Assets
533255000 usd
CY2021Q4 us-gaap Assets
Assets
423756000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8178000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6908000 usd
CY2022Q3 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
13771000 usd
CY2021Q4 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
12442000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29412000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27665000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1707000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
526000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
53068000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
47541000 usd
CY2022Q3 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
6823000 usd
CY2021Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
409000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
59891000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
47950000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
130000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
127000 usd
CY2022Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
453001000 usd
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
410411000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
648831000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
591349000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2381000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-227000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
279785000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
194968000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
473364000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
375806000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
533255000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
423756000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
101728000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
96131000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
298802000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
267156000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1339000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1275000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3905000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3927000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33292000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28091000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94237000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85345000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35163000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30533000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
110525000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90071000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
69794000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
59899000 usd
us-gaap Costs And Expenses
CostsAndExpenses
208667000 usd
us-gaap Costs And Expenses
CostsAndExpenses
179343000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
31934000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
36232000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
90135000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
87813000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1070000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
72000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1780000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
457000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
33004000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
36304000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
91915000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
88270000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1604000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5833000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7098000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7811000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
34608000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
30471000 usd
us-gaap Net Income Loss
NetIncomeLoss
84817000 usd
us-gaap Net Income Loss
NetIncomeLoss
80459000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
34550000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
34550000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
30471000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
30471000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
84755000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
84755000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
80459000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
80459000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.69
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107125000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115791000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106479000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116297000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116620000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125136000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115818000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127173000 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
34608000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
30471000 usd
us-gaap Net Income Loss
NetIncomeLoss
84817000 usd
us-gaap Net Income Loss
NetIncomeLoss
80459000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
23000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-8000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-449000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-85000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
74000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-23000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1415000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-265000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-314000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-77000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-739000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-35000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
34368000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
30371000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
82663000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
80159000 usd
us-gaap Profit Loss
ProfitLoss
84817000 usd
us-gaap Profit Loss
ProfitLoss
80459000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
31921000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
32121000 usd
cort Accretion Expense Income
AccretionExpenseIncome
2121000 usd
cort Accretion Expense Income
AccretionExpenseIncome
3805000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
599000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
783000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-29438000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2047000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1623000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1487000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1789000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
310000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1074000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2655000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10365000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2288000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1998000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-894000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
515000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3961000 usd
cort Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
1329000 usd
cort Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-860000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1747000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3123000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
6414000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
15000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1635000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1505000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
86935000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
118465000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
382000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
404000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
161718000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
308864000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
258422000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
312805000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-97086000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4345000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3596000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13182000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
88485000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
20819000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
20319000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-17223000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-95622000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27374000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18498000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77617000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76190000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50243000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94688000 usd
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
21975000 usd
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
9705000 usd
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
2816000 usd
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
0 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
523338000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10083000 usd
CY2021Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
33540000 usd
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
22520000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10142000 usd
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-166000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
23465000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
510802000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6661000 usd
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
29170000 usd
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
3238000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11131000 usd
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-34000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
26523000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
522675000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6225000 usd
CY2021Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
25775000 usd
CY2021Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4266000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10999000 usd
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-100000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
30471000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
540229000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
375806000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6544000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
7037000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10825000 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1124000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
22797000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
407811000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6597000 usd
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
9366000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10662000 usd
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-790000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
27412000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
442326000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12226000 usd
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
26187000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10631000 usd
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-240000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
34608000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
473364000 usd
cort Number Of Series Of Selective Cortisol Modulators
NumberOfSeriesOfSelectiveCortisolModulators
4 series
CY2022Q3 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
11171000 usd
CY2021Q4 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
11450000 usd
CY2022Q3 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
5902000 usd
CY2021Q4 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
6500000 usd
CY2022Q3 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
17073000 usd
CY2021Q4 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
17950000 usd
CY2022Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
11027000 usd
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12962000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
6046000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
4988000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4325000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3927000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3524000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2925000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
801000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1002000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12297000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13339000 usd
CY2022Q3 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
11683000 usd
CY2021Q4 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
11174000 usd
CY2022Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2058000 usd
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
842000 usd
CY2022Q3 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
1602000 usd
CY2021Q4 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
1351000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
909000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
150000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
863000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
809000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29412000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27665000 usd
CY2022Q3 cort Deposits For Clinical Trials
DepositsForClinicalTrials
4900000 usd
CY2021Q4 cort Deposits For Clinical Trials
DepositsForClinicalTrials
2900000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
375887000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
303283000 usd
CY2022Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
900000 usd
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1400000 usd
cort Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
P2Y
cort Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
P5M
CY2022Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0 usd
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2800000 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2800000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000 usd
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1600000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
578000 usd
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
530000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1687000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1574000 usd
CY2022Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2816000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6M
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.048
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
151000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
578000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1157000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1735000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
28000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1707000 usd
cort Number Of Stock Option Plans
NumberOfStockOptionPlans
1 stockoptionplan
CY2022Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
77000 usd
CY2021Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
47000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
197000 usd
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10631000 usd
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10999000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
32118000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
32272000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
34550000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
34550000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
30471000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
30471000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
84755000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
84755000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
80459000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
80459000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107125000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115791000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106479000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116297000 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9495000 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9345000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9339000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10876000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116620000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125136000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115818000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127173000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.69
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1600000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7100000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5800000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7800000 usd
CY2022Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
600000 usd
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1600000 usd
CY2022Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
8400000 usd
CY2022Q3 cort Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance
UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance
2400000 usd

Files In Submission

Name View Source Status
cort-20220930_cal.xml Edgar Link unprocessable
0001628280-22-028203-index-headers.html Edgar Link pending
0001628280-22-028203-index.html Edgar Link pending
0001628280-22-028203.txt Edgar Link pending
0001628280-22-028203-xbrl.zip Edgar Link pending
cort-20220930.htm Edgar Link pending
cort-20220930.xsd Edgar Link pending
cort93022ex101.htm Edgar Link pending
cort93022ex102.htm Edgar Link pending
cort93022ex103.htm Edgar Link pending
cort93022ex104.htm Edgar Link pending
cort93022ex311.htm Edgar Link pending
cort93022ex312.htm Edgar Link pending
cort93022ex321.htm Edgar Link pending
cort93022ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cort-20220930_def.xml Edgar Link unprocessable
cort-20220930_pre.xml Edgar Link unprocessable
cort-20220930_lab.xml Edgar Link unprocessable
cort-20220930_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending